Novacyt S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NCYT.L research report →
Companywww.novacyt.com
Novacyt S. A. , together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
- CEO
- Lyn Dafydd Rees
- IPO
- 2017
- Employees
- 234
- HQ
- Le Vésinet, FR
Price Chart
Valuation
- Market Cap
- $36.22M
- P/E
- -1.54
- P/S
- 1.81
- P/B
- 1.51
- EV/EBITDA
- -3.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.05%
- Op Margin
- -67.80%
- Net Margin
- -114.29%
- ROE
- -59.58%
- ROIC
- -33.77%
Growth & Income
- Revenue
- $20.39M · 3.88%
- Net Income
- $-23,296,211 · 44.21%
- EPS
- $-0.33 · 44.07%
- Op Income
- $-13,167,556
- FCF YoY
- 18.02%
Performance & Tape
- 52W High
- $86.00
- 52W Low
- $26.60
- 50D MA
- $36.23
- 200D MA
- $37.55
- Beta
- 0.97
- Avg Volume
- 351.55K
Get TickerSpark's AI analysis on NCYT.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NCYT.L Coverage
We haven't published any research on NCYT.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NCYT.L Report →